BridgeBio Oncology Therapeutics Inc. (BBOT)
BridgeBio Oncology Therapeutics Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in South San Francisco, CA, US. The stock last traded at $3.95, down 1.00% on the session, giving a market capitalisation of $316.4M. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of 0.39 implies it has historically moved less than the broad market.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
BridgeBio Oncology Therapeutics Inc. is most often compared with the following Healthcare names: